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Abstract 22 
Ki-67 is a nuclear protein universally expressed in proliferating vertebrate cells (1), a 23 
characteristic that underlies its widespread use as a cancer biomarker. It organises 24 
heterochromatin (2,3) and the mitotic chromosome periphery (2,4–6), but it is dispensable for 25 
cell proliferation in vivo2. It thus remains unclear whether Ki-67 confers any advantages to 26 
cancer cells. Here, using mouse models of breast and intestinal cancer, we show that Ki-67 27 
ensures gene expression programmes required for both carcinogenesis and tumour 28 
immunogenicity. We find that germline disruption of Ki-67 protects mice against intestinal 29 
tumourigenesis, while in mammary carcinoma cells, ablation of Ki-67 slows tumour growth 30 
and inhibits metastasis, despite the failure of cells lacking Ki-67 to induce an effective anti-31 
tumour immune response. Mechanistically, Ki-67 loss leads to widespread deregulation of 32 
gene expression, including genes involved in the epithelial-mesenchymal transition (EMT), 33 
immune responses and drug metabolism. This results in loss of mesenchymal and stem cell 34 
characteristics, downregulation of MHC class I expression and sensitisation to various drug 35 
classes. Our results suggest that, by structuring chromatin to allow global transcriptome 36 
changes, Ki-67 allows cancer cells to adapt to their environment. This is required for all stages 37 
of tumourigenesis and drug resistance, but, by maintaining tumour immunogenicity, it also 38 
confers a targetable vulnerability on cancer cells.  39 
 40 
Results and discussion 41 
Although Ki-67 is universally expressed in dividing cancer cells, cell proliferation is not 42 
affected by Ki-67 gene disruption in any cell type yet analysed in vitro, nor during mouse 43 
development2,5–7. However, Ki-67 might still be important in carcinogenesis since it 44 
contributes to organisation of chromatin2, which controls gene expression and thus cellular 45 
plasticity, a characteristic of cancer cells8,9. We first tested the involvement of Ki-67 in tumour 46 
initiation using an in vitro model. We transduced our previously generated Mki67+/+ or TALEN-47 
mutated Mki67-/- 3T3 fibroblasts10 with oncogenic mutant H-Ras (G12V), and assessed colony 48 
formation as an indicator of transformation. While H-RasG12V-transduced control 3T3 cells 49 
efficiently formed colonies, Mki67-/- 3T3 cells did not, indicating that Ki-67 expression is 50 
required for transformation (Extended Data Fig. 1). We next determined whether Ki-67 51 
knockout affects tumour initiation in vivo. We used a mouse model of colon carcinogenesis 52 
induced chemically by azoxymethane / dextran sodium sulphate (AOM-DSS) treatment11, and 53 
tested the effect of a germline TALEN-disruption of Ki-67 (Mki672nt∆/2nt∆) that we generated10. 54 
As expected, AOM-DSS efficiently induced colon tumours within 16 weeks in wild-type and 55 
Mki672nt∆/+ mice; however, no macroscopic lesions were observed in Mki672nt∆/2nt∆ mice 56 
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(Fig.1a,b). We confirmed that this was not due to an inability to induce inflammation, since 57 
DSS alone triggered similar inflammatory responses in mice of all genotypes (Extended Data 58 
Fig. 2). Furthermore, immune cell proliferation and differentiation in Mki672nt∆/2nt∆ mice 59 
appeared normal in response to haemolytic anaemia triggered by phenylhydrazine treatment 60 
(Extended Data Fig. 3). This suggests that Ki-67 is specifically required for initiation of 61 
tumourigenesis. To confirm this, we used a genetic model of intestinal tumourigenesis. We 62 
crossed Mki672nt∆/2nt∆ mice with Apc∆14/+ mice, which rapidly develop tumours in the intestine 63 
due to loss of the second allele of the Apc tumour suppressor gene12. While Apc∆14/+ 64 
Mki672nt∆/+ mice formed multiple intestinal tumours as expected, tumour burden was strongly 65 
reduced in Apc∆14/+ Mki672nt∆/2nt∆ mice (Fig. 1c,d). These results indicate that Ki-67 is required 66 
for efficient initiation of tumourigenesis induced either by an oncogene, chemical mutagenesis 67 
or loss of a tumour suppressor. 68 
 We next asked whether Ki-67 is required for tumour growth and metastasis from 69 
already transformed cells. As a first approach, we knocked down Ki-67 by stable shRNA in a 70 
commonly used aggressive human cervical cancer cell line, HeLa S3, and grafted the 71 
resulting cells and an shRNA control line into opposing flanks of athymic nude mice. Ki-67 72 
knockdown was maintained in vivo (Extended Data Fig. 4a,b) and, as expected, this did not 73 
affect cell proliferation (as shown by unchanged PCNA and mitotic indices; Extended data 74 
Fig. 4c,d). However, tumour growth was severely slowed (Fig. 2a) and histopathological 75 
analysis showed vast areas of necrosis and apoptosis accompanied by disorganised vascular 76 
and lymphatic networks, indicating disrupted angiogenesis (Fig. 2b,c). To ensure that 77 
phenotypes of Ki-67 downregulation were not specific to the tumour type or knockdown 78 
approach, we generated a biallelic MKI67 gene knockout (KO) by CRISPR-Cas9 in human 79 
MDA-MB-231 triple negative breast cancer cells (Extended Data Fig. 4e,f). As expected, 80 
MKI67-/- cells proliferated normally in vitro (Extended Data Fig. 4g,h) but tumours from 81 
xenografts in nude mice grew much slower than controls, again showing normal cell 82 
proliferation but defective angiogenesis (Fig. 2d-f). Thus, in xenograft experiments, Ki-67 83 
sustains tumour growth but not by controlling cell proliferation. 84 
To determine effects of Ki-67 loss in a mouse model that more closely mimics human 85 
breast cancer, we used 4T1 mammary carcinoma cells. This cell line is derived from BALB/c 86 
mice, is highly tumourigenic, spontaneously metastasises to distant organs13,14, and, when 87 
grafted in a syngeneic background, a biphasic tumour progression profile is observed due to 88 
an induced immune response15. As expected, CRISPR-Cas9-mediated Mki67 knockout did 89 
not affect 4T1 cell proliferation rates (Extended Data Fig. 5a-d). We engrafted WT and Ki-67 90 
knockout 4T1 cells orthotopically into mammary fat pads in both immune-proficient syngeneic 91 
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BALB/c mice and immunodeficient (athymic-nude and NOD/SCID) mice, the comparison of 92 
which should allow identification of the effects of the immune system. In immunodeficient 93 
mice, tumours from Mki67-/- 4T1 cells grew significantly slower than from Ki-67-expressing 94 
4T1 cells (Fig. 3a-c). In immune-proficient BALB/c mice, control 4T1 tumours established 95 
quickly and, as expected, initially regressed before regrowing (Fig. 3d). However, in these 96 
mice, Mki67-/- 4T1 cells formed primary tumours as efficiently as controls, but no initial 97 
regression occurred, overriding the slower growth of knockout tumours and resulting in higher 98 
final tumour burden than controls (Fig. 3d). This suggested a defective immune response in 99 
mice bearing Ki-67 knockout tumours. We analysed this by immunophenotyping of spleens 100 
and lymph nodes. The fraction of dendritic cells, B-cells and T-cells (except for T-reg) was 101 
reduced in Mki67-/- 4T1 tumour-bearing mice, as a result of a dramatic increase in cells 102 
positive for CD11b (a common myeloid marker, expressed by monocytes, neutrophils, NK 103 
cells, granulocytes, macrophages and myeloid-derived suppressor cells (MDSC)) (Extended 104 
Data Fig. 6). In agreement, immunohistological analysis revealed increased infiltration of 105 
MDSC in knockout tumours (using the MDSC marker, GR1; Fig. 3e), possibly indicating an 106 
immunosuppressive environment that protects the tumours against immune-mediated 107 
cytotoxicity.  108 
In immune-proficient mice, despite the impaired immune-response to Mki67-/- 4T1 cells 109 
and a consequently higher tumour burden, there were noticeably less metastases than from 110 
control 4T1 cells, although this failed to reach statistical significance (p = 0.13) (Fig 3f). 111 
However, the reduction in visible metastasis from Mki67-/- 4T1 cells was highly significant in 112 
immunodeficient mice (Fig. 3g) or in immune-proficient mice injected in the tail vein to 113 
circumvent the immune-targeting of tumour cells at the primary-site (Fig. 3h). We quantified 114 
micrometastases in nude mice by dissociating lung tissue after 2 weeks and growing cells in 115 
the presence of 6-thioguanine, to which 4T1 cells are resistant14. The number of metastatic 116 
cells from Ki-67 knockouts was reduced nearly 100-fold (Extended Data Fig. 7). These results 117 
highlight a trade-off for cancer cells, whereby Ki-67 expression sustains tumour growth and 118 
promotes metastasis, yet also confers efficient targeting by the immune system. 119 
Since we previously found that Ki-67 knockout in mouse NIH3T3 cells or knockdown 120 
in human cancer cells does not alter cell proliferation nor induce cell death, but disrupts 121 
chromatin organisation2 and alters gene expression, we hypothesised that the latter might 122 
explain the requirements for Ki-67 in tumourigenesis. To explore this idea we first compared 123 
transcriptomes of WT and Mki67-/- NIH3T3 cells by RNA-seq. Consistent with roles for Ki-67 124 
in maintaining global chromatin organisation, this revealed widespread changes in gene 125 
expression, with 2558 genes significantly deregulated in independent clones of Mki67-/- cells 126 
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(q < 0.05) (Extended Data Fig. 8a; Supplementary Table 1). Next, we investigated how 127 
transcriptomes are remodelled in 4T1 cells lacking Ki-67. In these cancer cells, Mki67 128 
knockout caused genome-scale gene expression alterations: 4979 genes were deregulated, 129 
of which 1239 and 585 genes were >2-fold down-regulated and up-regulated, respectively 130 
(Fig. 4a; Extended Data Fig. 8b; Supplementary Table 2). There was little overlap in the 131 
deregulated genes between Mki67-/- (epithelial) and NIH3T3 (mesenchymal) cells (Extended 132 
Data Fig. 8b; Supplementary Tables 1,2) suggesting that Ki-67 ensures gene expression 133 
programmes in different cell types by maintaining chromatin organisation rather than directly 134 
regulating specific genes. RNA-seq of early stage tumours from WT and Ki-67 mutant 4T1 135 
cells grafted into nude mice showed that Ki-67-dependent transcriptome changes were 136 
preserved in vivo (Fig. 4b). 137 
We performed pathway analysis of genes highly deregulated in Ki-67 knockout 4T1 138 
cells to better understand the links between Ki-67-mediated gene expression control and 139 
tumourigenesis. We found upregulation of Notch targets and downregulation of genes 140 
involved in the inflammatory response, Wnt pathway and the EMT (Fig. 4c) which we 141 
validated by qRT-PCR (Extended Data Fig. 8c). Importantly, although the Notch pathway is 142 
oncogenic in T cell acute lymphoid leukaemia, it can act as a tumour suppressor in specific 143 
cellular contexts16, can block Wnt signaling17,18 (a driver of tumourigenesis, cell stemness and 144 
the EMT) and induce drug resistance19. We confirmed Notch pathway upregulation at the 145 
protein level (Fig. 4d). We further verified that Ki-67 knockout 4T1 cells had lost expression 146 
of the mesenchymal marker vimentin but upregulated E-cadherin, and had a more epithelial 147 
morphology (Fig. 4e). Downregulated genes were enriched in targets of nuclear factor 148 
erythroid 2-related factor 2 (NFE2L2), which upregulates genes in response to oxidative 149 
stress; interferon regulatory factor 8 (IRF8); polycomb-repression complex 2 (PRC2), which 150 
mediates H3K27me3 and is a well-characterised regulator of the EMT20,21; and the 151 
pluripotency factors Nanog and Sox2 (Extended Data Fig. 8d). We focused on PRC2 as we 152 
previously found10 that in human osteosarcoma U2OS cells, Ki-67 binds to the essential 153 
PRC2 component SUZ12. To test whether the repression of the EMT in Ki-67 knockout 154 
depends on PRC2, we disrupted Suz12 or Ezh2 in WT and Mki67-/- 4T1 cells using CRISPR-155 
Cas9. This partially rescued expression of vimentin (Extended Data Fig. 8e,f). However, it did 156 
not restore tumour growth rates nor metastasis in vivo from Mki67-/- 4T1 cells, nor affect 157 
tumourigenicity of control cells, in nude mice (Extended Data Fig. 8g). Thus, the PRC2 158 
complex activity is restrained by Ki-67, but does not in itself have either oncogenic or tumour 159 
suppressive activity in this system. As such, the reported PRC2 roles in cancer22,23 might not 160 
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apply generally, and a single chromatin regulation pathway cannot account for Ki-67 roles in 161 
supporting the EMT and tumourigenesis. 162 
Like Ki-67, the EMT is required for metastasis in some mouse cancer models24,25. The 163 
EMT is also closely associated with a stem-like state26–28, as well as resistance to 164 
chemotherapeutic drugs29 and induction of immune responses30. We therefore next 165 
investigated the importance of Ki-67 for these three EMT-linked characteristics. 166 
First, we analysed two indicators of tumour cell stemness: the ability to form spheroids 167 
in the absence of adhesion to a surface26,31, and aldehyde dehydrogenase activity32,33. Both 168 
parameters were strongly reduced in Ki-67 knockout 4T1 cells (Fig. 4f,g).  169 
Second, we noticed that 26 genes involved in drug metabolism were downregulated in 170 
Ki-67 knockout 4T1 cells, while only one was upregulated, suggesting that Ki-67 expression 171 
might determine sensitivity to chemotherapeutic drugs (Extended Data Fig. 9a,b). To test this, 172 
we performed an automated gene-drug screen using the Prestwick chemical library, 173 
composed of 1283 FDA-approved small molecules, as well as salinomycin, a positive control 174 
found to target cancer stem cells34, and 6-thioguanine, which was originally used to isolate 175 
4T1 cells13. Control 4T1 cells were sensitive to 102 drugs at 10µM concentration, while the 176 
two Mki67-/- clones were sensitive to 99 and 98 respectively, with 82 hits common to the three 177 
cell lines (Extended Data Fig. 9c; Supplementary Data). This suggests that Ki-67 loss does 178 
not qualitatively alter the drug-sensitivity profiles. We next determined the IC50 of 10 common 179 
hits used in cancer therapy. Importantly, Mki67-/- cells were markedly more sensitive to all the 180 
molecules tested (Fig. 4h; Extended Data Fig. 9d).  181 
Third, genes directing mouse major histocompatibility complex (MHC) class I-mediated 182 
antigen presentation Tap2, Psmb8 and Psmb9 were downregulated in Mki67-/- 4T1 cells 183 
(Extended Data Fig. 8c; Supplementary Table 2). Flow cytometry confirmed lower expression 184 
of the mouse MHC class I molecules H2D and H2K (Fig. 4i), providing an explanation for how 185 
Ki-67 knockout affects tumour recognition by the immune system. We obtained similar results 186 
in human MKI67-/- MDA-MB-231 cells, implying that roles of Ki-67 in maintaining MHC 187 
expression are conserved across species (Extended Data Fig. 10).  188 
The above results show that Ki-67 is not required for cancer cell proliferation in vivo, 189 
but supports coherent transcriptional programmes that are involved in tumour cell plasticity, 190 
drug resistance and induction of immune responses. Together, these likely account for the 191 
roles of Ki-67 in tumourigenesis revealed in this study (Fig. 4j). Clues to its biochemical 192 
mechanism of action are suggested by the fact that Ki-67 is an intrinsically disordered protein 193 
(IDP) and behaves as a surfactant for mitotic chromatin5. Since we previously found that 194 
heterochromatin is more dispersed in cells lacking Ki-67 (ref. 2), we propose that these 195 
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properties may also allow Ki-67 to regulate interphase chromatin. Due to their conformational 196 
flexibility, IDPs can act as hubs to bind many protein partners35, and we previously identified 197 
many chromatin regulators interacting with Ki-67 (ref. 2). However, disrupting one such 198 
interactor, the PRC2 complex, does not restore tumourigenic capacity to Ki-67 mutant cancer 199 
cells, consistent with the idea that Ki-67 may act more globally. 200 
While it has long been thought that global changes in nuclear structure observed in 201 
cancer cells might contribute functionally to carcinogenesis36, mechanistic insight into this 202 
question has been lacking. We speculate that the alterations of nuclear organisation seen in 203 
cancer cells may reflect their increased cellular plasticity. By binding multiple chromatin 204 
regulators and organising the transcriptome at a genome scale, Ki-67 might contribute to both 205 
nuclear structuration and cellular plasticity, thereby conferring on cancer cells the ability to 206 
adapt to their environment. 207 
 208 
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 1 
Methods 1 
 2 
Cell lines and mice 3 
4T1 cells were provided by Robert Hipskind (IGMM, Montpellier); MDA-MB-231 cells were 4 
obtained from SIRIC, Montpellier. NIH 3T3, 4T1, MDA-MB-231 and S3 HeLa cells were 5 
grown in Dulbecco modified Eagle medium (DMEM - high glucose, pyruvate, GlutaMAX – 6 
Gibco® Life LifeTechnologies) supplemented with 10% foetal bovine serum (SIGMA or 7 
DUTSCHER). Cells were grown under standard conditions at 37°C in humidified incubator 8 
containing 5% CO2. 9 
6-8 weeks-old female BALB/c (BALB/cOlaHsd), athymic nude (Hsd:Athymic 10 
Foxn1nu/Foxn1+), and NOD.SCID (NOD.CB17-Prkdcscid/NCrHsd) mice were purchased from 11 
Envigo. C57BL/6 Apc∆14 mice12 were provided by Philippe Jay (IGF, Montpellier).  12 
 13 
Animal studies 14 
All animal experiments were performed in accordance with international ethics standards 15 
and were subjected to approval by the Animal Experimentation Ethics Committee of 16 
Languedoc Roussillon (n°APAFIS#8637-2017012311188975v3). 17 
 18 
Antibodies and plasmids  19 
Antibodies: Ki-67 (clone SP6; Abcam), cyclin A2 (6E6; Novocastra), PCNA (ab18197; 20 
Abcam), β-catenin (BD610154; BD-Bioscience), Ras (G12V Mutant Specific D2H12, 21 
#14412; CST), actin (A2066; Sigma), vimentin (D21H3, #5741; CST), E-Cadherin (24E10, 22 
#3195; CST), Suz12 (D39F6, #3737; CST), H3K27me3 (#39155, Active Motif),  H2Dd-FITC 23 
(#553579; BD Biosciences), H2Kd-PE (SF1-1.1; BD Biosciences), HLA-PE (EMR8-5; BD 24 
Biosciences). 25 
Lentiviral Vectors used: LentiCRISPRv2 (Addgene #52961), pMD2.G (Addgene #12259), 26 
psPAX2 (Addgene #12260). pHIV-Luc-ZsGreen (Addgene #39196) was used to generate 27 
bicistronic lentivirus that expresses both Luciferase and Zsgreen. 28 
Retroviral vectors used: pBabe-puro (Addgene #1764), pBabe-puro H-RasG12V (Addgene 29 
#1768). gag/pol (retroviral packaging) and Maloney (envelope) were gift from Leatitia 30 
Linares (IRCM, Montpellier).  31 
pUC57-U6-sgRNA (#51132, Addgene); Cas9-VP12 (#72247, Addgene), modified by adding 32 
T2A-GFP at the C-terminal end (gift from Edouard Bertrand, IGMM). 33 
 34 
CRISPR/Cas9-mediated genome editing 35 
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 2 
The sgRNAs targeting mouse Mki67 exon 3 or human MKI67 exon 6 and non-targeting 36 
control sequences were previously designed37, and cloning of the target sequence into the 37 
LentiCRISPRV2 lentiviral vector was conducted as described37. Lentiviruses encoding the 38 
sgRNA targeting sequences were produced. Transduced cells (4T1 and MDA-MB-231) 39 
expressing CRISPR/Cas9 were selected using puromycin. Resistant cells were isolated and 40 
seeded as single cell clones in 96 well-plates.  41 
For Suz12 and Ezh2 knockout, sgRNA targeting sequences37 were synthesised with BpiI 42 
sticky ends and cloned into the pUC57-U6-sgRNA vector. Cas9-VP12-T2A-GFP and sgRNA 43 
vectors were transfected into 4T1 WT and Ki-67-/- #2 clone using Lipofectamine 2000 44 
(ThermoFisher). 24h post-transfection, GFP-positive cells were sorted i96-well plates by 45 
flow cytometry (FACS Aria, BD). After 10-12 days of culture, colonies were picked and 46 
screened (Cellomics, Thermo), using Suz12 or H3K9me3 antibodies. Positive knockout 47 
clones were confirmed by PCR, IF and western blotting. 48 
 49 
AOM-DSS-induced colon carcinogenesis 50 
Mice (Mki67+/+; Mki67+/2nt∆ & Mki672nt∆/2nt∆) were given a single intraperitoneal injection of 51 
AOM (10 mg/kg in 0.9% saline; A5486, Sigma-Aldrich), and one week later, 2% Dextran 52 
Sodium Sulfate (DSS; MP Biomedicals) was administered in the drinking water for 7 53 
consecutive days. Mice were sacrificed at week 16-post AOM-DSS treatment and colon 54 
tissues were removed.  55 
Colons were flushed and fixed overnight in neutral buffered formalin (10%) before paraffin 56 
embedding. Briefly, 4µm thick sections were dewaxed in xylene and rehydrated in graded 57 
alcohol baths. Slides were incubated in 3% H2O2 for 20 min and washed in PBS to quench 58 
endogenous peroxidase activity. Antigen retrieval was performed by boiling slides for 20 min 59 
in 10 mM sodium citrate buffer, pH 6.0. Nonspecific binding sites were blocked in blocking 60 
buffer (TBS, pH 7.4, 5% dried milk, 0.5% Triton X-100) for 60 min at RT. Sections were 61 
incubated with anti- β-catenin antibody diluted in blocking buffer overnight at 4°C. Envision+ 62 
(Dako) was used as a secondary reagent. Signals were developed with DAB (Sigma-63 
Aldrich). After dehydration, sections were mounted in Pertex (Histolab) and imaged using 64 
the Nanozoomer-XR Digital slide Scanner C12000-01 (Hamamatsu). 65 
 66 
DNA replication assay, EdU labelling 67 
Cells were treated with 10 µM 5-ethynyl-2'-deoxyuridine (EdU; LifeTechnologies) for the 68 
indicated time, harvested, washed once with cold PBS, resuspended in 300µL cold PBS 69 
and fixed with 700µL ice-cold 100% ethanol. Click reaction was performed according to the 70 
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 3 
manufacturer instructions (Click-iT™ Plus EdU Alexa Fluor™ 647 Flow Cytometry Assay 71 
Kit; Invitrogen) and cells were analysed by flow-cytometry (BD FACSCanto II). FlowJo® 72 
software was used for analysis.  73 
 74 
Mammosphere assay 75 
The mammosphere formation assay was performed as previously described38. Briefly, 500 76 
cells were plated per well in a low-adherence 96-well plate coated with poly-2-hydroxyethyl-77 
methacrylate (poly-Hema). After 7 days in culture (37°C, 5% CO2), images of formed 78 
mammospheres were acquired and counted using automated high-content microscopy 79 
analysis (Cellomics, Thermo).  80 
 81 
Aldehyde Dehydrogenase 1 (ALDH1) activity  82 
ALDH1 enzymatic activity was determined using the ALDEFLUOR kit (Stem Cell 83 
Technologies) according to the manufacturer instructions. For each sample, half the 84 
cell/substrate mixture was treated with diethylaminobenzaldehyde (DEAB; ALDH inhibitor). 85 
ALDEFLUOR/DEAB treated cells were used to define negative gates. FACS was performed 86 
with ≥105 cells. 87 
 88 
Xenografts 89 
Animals were housed in the animal facility of IGMM and were maintained in a pathogen-free 90 
environment and fed ad libitum.  91 
To generate primary tumours, 106 cells (4T1) or 3x106 cells (MDA-MB-231) of log-phase 92 
viable ‘mouse pathogen-free’ (Test: IMPACT1, Iddex) were implanted into the fourth inguinal 93 
mammary gland (in 50 µl PBS (4T1) or 200 µl PBS (MDA-MB-231)).  94 
Primary tumour volume was measured every week by electronic calliper using the formula 95 
“p/6*S2 (Smaller radius)*L (Larger radius)”. 96 
At the end of the experiment, following sacrifice, primary tumours were excised and fixed 97 
over-night in neutral buffered formalin (10%) before paraffin embedding (see above). IHC 98 
analysis of Ki-67 expression of the different tumour tissue sections was conducted as 99 
described above.  100 
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 4 
Visualisation of lung metastases  101 
Dissected lungs were stained with 15% India Ink diluted in distilled water, and subsequently 102 
washed with 5 ml Fekete’s solution (40 ml glacial acid acetic, 80 ml formalin, 580 ml ethanol 103 
100%, 200 ml water). A binocular microscope connected to a digital camera was used to 104 
visualise and count the metastatic nodules.  105 
Automated drug library screen 106 
We performed an initial screen of all 1,280 FDA-approved drugs in the Prestwick Chemical 107 
Library (Prestwick Chemical, Illkirch-Graffenstaden, France) at 10 μM in white clear-bottom 108 
96-well plates. Briefly, we prepared seeding solutions at a density of 2 × 105 cells/mL in 109 
DMEM complete medium (10%FBS), and dispensed 100 μL into 96-well plates using a 110 
Multidrop Combi Dispenser (Thermo Scientific™). Next, we prepared 1x treatment solutions 111 
of the Prestwick compounds in DMEM complete medium at a concentration of 10 μM using 112 
a Tecan EVO200 robotic liquid handling system (Tecan Trading AG). We removed medium 113 
from the pre-seeded 96-well plates and we dispensed 100 μL of 1x treatment solutions using 114 
the Tecan robot. We incubated plates at 37°C, 5% CO2 for 48 h in an automated incubator 115 
(Cytomat, Thermo Scientific™) associated with the Tecan robot. After treatment, cell 116 
survival was determined using the CellTiter-Glo® Luminescent Cell Viability Assay 117 
(Promega Corporation) in accordance with the manufacturer's instructions. Luminescence 118 
signal was automatically measured with a Tecan Infinity F500 microplate reader (Tecan 119 
Trading AG). “Hits” were identified applying the Z-score statistical method (see statistical 120 
analysis section). The same method was used for subsequent dose-response experiments 121 
on selected “hits”. 122 
 123 
Induction of anemia with PHZ 124 
Anemia was induced in adult Mki672nt∆/2nt∆ mice and littermate controls (Mki67+/2nt∆) by 125 
injection of 40 mg/kg phenylhydrazine (PHZ) on days 0, 1, and 3. Animals were sacrificed 126 
on day 5 and blood, spleen and bone marrow were collected. Hematocrit was measured as 127 
previously described39. Cell suspensions were generated and immunophenotyping 128 
performed by flow cytometry.  129 
Immunophenotyping and flow cytometry analyses 130 
Cells isolated from peripheral lymph nodes tumor (draining and non-draining for tumor-131 
bearing mice) as well as spleen and bone marrow, were stained with Sytox blue or Live/dead 132 
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 5 
fixable viability dye (Life Technologies and eBioscience, respectively) together with the 133 
appropriate conjugated anti-CD3, CD45, CD62L, CD4, CD8, CD44, CD25, F4/80, CD19, 134 
B220, NK1.1, Gr1, CD11b, CD11c, Ter119, CD71 and Foxp3 antibodies 135 
(eBioscience/ThermoFisher or Becton Dickinson, San Diego, CA). Intracellular staining for 136 
Foxp3 was performed using the eBioscience Fixation/Permeabilization kit. 137 
Cells were analysed on a FACS Fortessa (BD Biosciences) flow cytometer. Data analyses 138 
were performed using FlowJo Mac v.10 (Tree Star) or DIVA (Becton Dickinson) software. 139 
 140 
Prior to intracellular cytokine stainings, cells were activated with PMA (Sigma-Aldrich; 100 141 
ng/ml)/ Ionomycin (Sigma-Aldrich; 1ug/ml) in the presence of brefeldin A (Sigma-Aldrich; 142 
10ug/ml) for 3.5-4h at 37oC. Cell surface staining was performed, after which cells were 143 
fixed and permeabilised using a fixation/permeabilization kit (BD Biosciences or 144 
eBioscience) followed by intracellular cytokine staining.  145 
 146 
Antibodies used for immunophenotying 147 
 148 
 clone fluorochrome reference 
Murine anti-CD3 145-2C11 V421 562600 
Murine anti-CD4 RM4-5 BV711 563726 
Murine anti-CD8 53-6.7 FITC 553031 
Murine anti-CD8 53-6.7 AF700 564983 
Murine anti-CD62L MEL-14 APC 553152 
Murine anti-CD44 IM7 PE-CF594 562464 
Murine anti-CD45 30-F11 AAF 47-0451-82 
Murine anti-CD25 PC61 AAF 47-0251-82 
Murine anti-CD19 1D3 BV650 563235 
Murine anti-NK11 PK136 APC 550627 
Murine anti-CD11b M1/70 BV605 563015 
Murine anti-CD11c HL3 PE 557401 
Murine anti-LY6G RB6-8C5 PE-CF594 562710 
Murine anti-LY6C AL-21 V450 560594 
Murine anti-F4/80 BM8 PEC7 25-4801-82 
Murine anti-Foxp3 FJK-16S PEC7 25-5773-82 
Murine anti-TNFα MP6-XT22 PE 12-7321-82 
Murine anti-IL-2 JES6-5H4 PEC7 560538 
Murine anti-IFNγ XMG1.2 APC 17-7311-82 
Murine anti-IL17A TC11-18H10 BV605 564169 
Murine anti-Ter119 Ter-119 (hamster) FITC 557915 
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 6 
Murine anti-CD71 C2 BV605 563013 
Murine anti-B220 RA3-6B2  
 
eF780 47-0452-82 
 149 
Cell extracts and Western-blotting 150 
Frozen cell pellets (harvested by trypsinization, washed with cold PBS) were lysed directly 151 
in Laemmli buffer at 95°C. Protein concentrations were determined by BCA protein assay 152 
(Pierce Biotechnology). Proteins were separated by SDS-polyacrylamide gel 153 
electrophoresis (SDS-PAGE) (7.5% and 12.5% gels) and transferred to Immobilon 154 
membranes (Milipore) at 1.15 mA/cm2 for 120 min with a semi-dry blotting apparatus. 155 
Membranes were blocked in TBS-T pH 7.6 (20 mM Tris, 140mM NaCl, 0.1% Tween-20) 156 
containing non-fat dry milk (5%), incubated with the primary antibody for 2 hours at RT or 157 
over-night at 4°C, washed several times with TBS-T for a total of 45 minutes, incubated with 158 
secondary antibody at 1/5000 dilution for 1 hour at RT and washed several times in TBS-T. 159 
Signals were detected using Western Lightning Plus-ECL (PerkinElmer) and Amersham 160 
HyperfilmTM (GE Healthcare). 161 
 162 
qRT-PCR 163 
For reverse transcription (cDNA synthesis), 500 ng of purified RNA in total volume of 10µl, 164 
extracted by RNeasy Mini Kit (Qiagen), were mixed with 1µl of 10mM dNTPs mix 165 
(LifeTechnologies) and 1µl of 50µM random hexaprimers (NEB). Samples were incubated 166 
at 65°C for 5 minutes, transferred to ice, 5µl 5x First Strand Buffer, 2µLl100mM DTT and 1µl 167 
RNasin RNase Inhibitor (Promega) were added and samples were incubated at 25°C for 10 168 
minutes, 42°C for 2 minutes. 1µl of SuperScript® III Reverse Transcriptase 169 
(LifeTechnologies) was added to each sample and incubated at 50°C for 60 minutes, 70°C 170 
for 15 minutes.  171 
qPCR was performed using LightCycler® 480 SYBR Green I Master (Roche) and 172 
LightCycler® 480 qPCR machine. The reaction contained 5ng of cDNA, 2µl of 1μM qPCR 173 
primer pair, 5µl 2x Master Mix, and final volume made up to 10µl with DNase free water. 174 
Primers used for both mouse (Mki67) and human (MKI67) Ki-67 in addition to the 175 
housekeeping genes are similar to those used by Sobecki et al., 2016. qPCR was conducted 176 
at 95°C for 10 min, and then 40 cycles of 95°C  20s, 58°C 20s and 72°C 20s. The specificity 177 
of the reaction was verified by melting curve analysis.  178 
 179 
PCR primers used in this study. 180 
 181 
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 7 
Gene name Sequence PrimerBank 
ID 
Reference 
Actb Fw- GGCCCAGAGCAAGAGAGGTATCC 
Rv- ACGCACGATTTCCCTCTCAGC 
 
- 40 
Gapdh Fw- CGTCCCGTAGACAAAATGGT 
Rv- TGACTGTGCCGTTGAATTTG 
- 41 
B2m Fw- ACGTAACACAGTTCCACCCG 
Rv- CAGTCTCAGTGGGGGTGAAT 
- 42 
Gusb Fw- AACAACACACTGACCCCTCA 
Rv- ACCACAGATCGATGCAGTCC 
- 42 
Zeb2 Fw- GGCAAGGCCTTCAAGTACAA 
Rv- AAGCGTTTCTTGCAGTTTGG 
- 43 
Twist1 Fw- AGCGGGTCATGGCTAACG 
Rv- GGACCTGGTACAGGAAGTCGA 
- 44 
Tap2 Fw- CTGGCGGACATGGCTTTACTT 
Rv- CTCCCACTTTTAGCAGTCCCC 
7549791a1 45 
Psmb8 Fw- ATGGCGTTACTGGATCTGTGC 
Rv- CGCGGAGAAACTGTAGTGTCC 
6755208a1 45 
Zeb1 Fw- CGCCATGAGAAGAACGAGGAC 
Rv- CTGTGAATCCGTAAGTGCTCTTT 
357197186c2 45 
Vim Fw- CTGCTTCAAGACTCGGTGGAC 
Rv- ATCTCCTCCTCGTACAGGTCG 
227430362c2 45 
Epcam Fw- GGAGTCCCTGTTCCATTCTTCT 
Rv- GCGATGACTGCTAATGACACCA 
11229327c3 45 
Hes1 Fw- GATAGCTCCCGGCATTCCAAG 
Rv- GCGCGGTATTTCCCCAACA 
31560817c2 45 
Lef1 Fw- GCCACCGATGAGATGATCCC 
Rv- TTGATGTCGGCTAAGTCGCC 
118130133c1 45 
Aldh1l2 Fw- TTTCCTGAGGGGATCAAGGC 
Rv- GACCTCGAATCCAGTTATGCAA 
283436217c3 45 
Aldh3a1 Fw-AATATCAGTAGCATCGTGAACCG 
Rv- GGAGAGCCCCTTAATCGTGAAA 
6680676a1 45 
 182 
 183 
Colony formation assay 184 
3T3 wild-type (WT) and two Ki-67 TALEN-mutant clones were transduced with either empty 185 
control or H-RasG12V expressing retroviruses. After verification of RasG12V expression, cells 186 
were seeded at 105 cells/well (6 well-plate) in triplicate and allowed to grow for 2-weeks 187 
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 8 
(media were changed every 2 days). Cells were then fixed (4% formaldehyde) and stained 188 
with 0.5% (w/v) crystal violet to visualise the colonies formed. 189 
 190 
RNA sequencing library prep 191 
Total RNA was extracted using Trizol (Life Technologies) following manufacturer's 192 
instructions from wild type and two clones of 4T1 Ki-67 knockout cell lines. RNA integrity 193 
was analysed on Agilent 2100 bioanalyzer. For library preparation, cDNA synthesis was 194 
performed on rRNA-depleted samples using the TruSeq Stranded Total RNA Library 195 
Preparation (RS-122-2301). All sequencing libraries were prepared in two or three biological 196 
replicates. Indexed cDNA libraries were sequenced by MGX (Montpellier) on Illumina 197 
HiSeq2000 with a single 50 bp read and a 10 bp index read. 198 
 199 
Sequencing of cDNA libraries and data processing 200 
FastQC was used to perform quality control of the sequencing. Using the tool STAR 201 
2.6.0a(2), all the reads that passed the quality control were aligned to the mouse reference 202 
genome (GRCm38.p6) and the counts per gene were quantified. The release 93 of the 203 
Ensembl mouse genome annotations were used for establishing the coordinates of each 204 
gene and their transcripts. Differential expression analysis was performed in R using the 205 
DESeq2(2) library embedded in an in-house script. After normalization of the read counts 206 
per gene, a negative binomial generalised linear model was fitted considering single factor 207 
design for assessing the differential expression between Mki67 knockout and wild-type 208 
samples. Gene set enrichment analysis of the 4T1 Mki67-/- cell line vs WT cell line was 209 
performed using the javaGSEA(3) desktop application with a log-fold-change pre-ranked 210 
gene list. 211 
 212 
Gene set enrichment for transcription factors. 213 
The gene set enrichment was performed over the ENCODE and ChEA Consensus TFs from 214 
ChIP-X gene set, which contains consensus target genes for transcriptions factors present 215 
in ENCODE and ChEA databases. The p value was computed with the Fisher Exact test 216 
and then adjusted for multiple hypotesis testing in order to obtain the FDR (false discovery 217 
rate) adjusted p-value. 218 
 219 
MHC class I expression analysis 220 
The MHC class I expression analysis was performed as previously described46. 4T1 CTRL 221 
and Mki67-/- cells were incubated with anti-H2Dd-FITC, anti-H2Kd-PE or control isotypes, and 222 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/712380doi: bioRxiv preprint first posted online Jul. 24, 2019; 
 9 
MDA-MB-231 CTRL and Mki67-/- cells were incubated with anti-HLA-PE or control isotype, 223 
in PBS/BSA 2% at 4°C for 20 min. After 2 washes in PBS/BSA 2%, cells were analysed by 224 
FACS.  225 
 226 
Statistical analysis  227 
Significant differences between the different experimental groups were tested using an 228 
unpaired two-tailed Student’s t-test or ANOVA in Prism 5 (GraphPad). For all analyses, p 229 
values < 0,05 (*), p values < 0,01 (**), p values < 0,001 (***) and p values < 0,0001 (****) 230 
were considered to indicate a statistically significant result. 231 
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